TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies.

PURPOSE TGFBR1*6A is a hypomorphic polymorphic allele of the type I transforming growth factor beta receptor (TGFBR1). TGFBR1*6A is a candidate tumor susceptibility allele that has been associated with an increased incidence of various types of cancer. This study was undertaken to analyze all published case-control studies on TGFBR1*6A and cancer and determine whether TGFBR1*6A is associated with cancer. PATIENTS AND METHODS All published case-control studies assessing the germline frequency of TGFBR1*6A were included. Studies assessing TGFBR1*6A in tumors were excluded. The results of seven studies comprising 2,438 cases and 1,846 controls were pooled and analyzed. RESULTS Overall, TGFBR1*6A carriers have a 26% increased risk of cancer (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.07 to 1.49). Cancer risk for TGFBR1*6A homozygotes (OR, 2.53; 95% CI, 1.39 to 4.61) is twice that of TGFBR1*6A heterozygotes (OR, 1.26; 95% CI, 1.04 to 1.51). Analysis of various types of tumors shows that TGFBR1*6A carriers are at increased risk of developing breast cancer (OR, 1.48; 95% CI, 1.11 to 1.96), hematological malignancies (OR, 1.70; 95% CI, 1.13 to 2.54), and ovarian cancer (OR, 1.53; 95% CI, 1.07 to 2.17). Carriers of TGFBR1*6A who are from the United States are at increased risk of colorectal cancer (OR, 1.38; 95% CI, 1.02 to 1.86). However, Southern European TGFBR1*6A carriers have no increased colorectal cancer risk. There is no association between TGFBR1*6A and bladder cancer. CONCLUSION TGFBR1*6A is emerging as a highfrequency, low-penetrance tumor susceptibility allele that predisposes to the development of breast, ovarian, and colorectal cancer, as well as hematologic malignancies.

[1]  D. Eccles,et al.  Transforming Growth Factor (cid:1) Receptor 1 Polyalanine Polymorphism and Exon 5 Mutation Analysis in Breast and Ovarian Cancer , 2022 .

[2]  M. Leppert,et al.  Uncommon TGFBRI allele is not associated with increased susceptibility to colon cancer , 2001, Genes, chromosomes & cancer.

[3]  M. Spiroski,et al.  TbetaR-I(6A) polymorphism is not a tumor susceptibility allele in Macedonian colorectal cancer patients. Correspondence re: B. Pasche et al. Type I TbetaR-I(6A) Is a Candidate Tumor Susceptibility Allele. Cancer Res., 58: 2727-2732, 1998. , 2001, Cancer research.

[4]  S. Thorgeirsson,et al.  Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. , 2001, Cancer research.

[5]  J. Graff,et al.  Transforming Growth Factor-β Receptor Type I Gene Is Frequently Mutated in Ovarian Carcinomas , 2001 .

[6]  E. Ziv,et al.  Association between the T29-->C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. , 2001, JAMA.

[7]  E. Zwarthoff,et al.  The chromosome 9q genes TGFBR1, TSC1, and ZNF189 are rarely mutated in bladder cancer , 2001, The Journal of pathology.

[8]  B. Pasche.  Role of transforming growth factor beta in cancer , 2001, Journal of cellular physiology.

[9]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[10]  J. Massagué,et al.  Controlling TGF-β signaling , 2000, Genes & Development.

[11]  H. Ostrer,et al.  TβR-I(6A) Is a Candidate Tumor Susceptibility Allele , 1999 .

[12]  H. Hollema,et al.  Structural alterations of transforming growth factor‐β receptor genes in human cervical carcinoma , 1999, International journal of cancer.

[13]  L. Wakefield,et al.  Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency , 1998, Nature Medicine.

[14]  E. Dmitrovsky,et al.  Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. , 1998, Cancer research.

[15]  L. Aaltonen,et al.  Mutations in the SMAD4/DPC4 gene in juvenile polyposis. , 1998, Science.

[16]  K. Miyazono,et al.  HNPCC associated with germline mutation in the TGF-β type II receptor gene , 1998, Nature Genetics.

[17]  C. Weghorst,et al.  Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. , 1997, Carcinogenesis.

[18]  Luzhe Sun,et al.  Demonstration That Mutation of the Type II Transforming Growth Factor β Receptor Inactivates Its Tumor Suppressor Activity in Replication Error-positive Colon Carcinoma Cells (*) , 1995, The Journal of Biological Chemistry.

[19]  M. Reiss,et al.  Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. , 1995, Cancer research.

[20]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[21]  J. Willson,et al.  Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells , 1994 .

[22]  S Greenland,et al.  A general estimator for the variance of the Mantel-Haenszel odds ratio. , 1986, American journal of epidemiology.

[23]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.